Rosiglitazone promotes pancreatic regeneration in experimental model of acute pancreatitis.
Acute pancreatitis is an inflammatory disease of the pancreas caused by release of activated digestive enzymes in the pancreas. A number of therapeutic options have been explored for acute pancreatitis, but none has been unambiguously proven to be effective. Rosiglitazone has been shown to be efficacious in acute pancreatitis; thus, the present study was planned to evaluate the effect of rosiglitazone on pancreatic regeneration. Pancreatitis was induced by l-arginine in rats which were divided into three groups: cholecystokinin (CCK-8), rosiglitazone and vehicle. Rats were sacrificed at four time points after induction of pancreatitis i.e. 24h, day 3, day 14 and day 28 for determination of biochemical parameters and histological examination. Rate of DNA synthesis, immunohistochemistry and RT-PCR were performed at day 3 and day 7. Drug administration was started 2h after last L-arginine injection and continued till the day of sacrifice. The lower levels of enzyme in rosiglitazone-treated group compared to vehicle group proved the efficacy of rosiglitazone treatment in reducing severity of acute pancreatitis. The nucleic acid content and rate of DNA synthesis were significantly higher in rosiglitazone group indicating promotion of pancreatic regeneration. The histopathological score were lower in rosiglitazone group. Rosiglitazone treatment promoted pancreatic regeneration after acute injury. Currently, only symptomatic treatment is available, regeneration of pancreatic tissue can be a future strategy in the management of acute pancreatitis. Further studies are required to support the findings of the present study.
Sidhu
Shabir
S
Department of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India. sidhushabir@rediffmail.com
Pandhi
Promila
P
Malhotra
Samir
S
Vaiphei
Kim
K
Khanduja
K L
KL
D000208:Acute Disease; D000818:Animals; D001120:Arginine / Q000633:toxicity; D004247:DNA / Q000096:biosynthesis; D004195:Disease Models, Animal; D005260:Female; D008297:Male; D047495:PPAR gamma / Q000819:agonists*; D010195:Pancreatitis / Q000188:drug therapy* / Q000503:physiopathology; D051381:Rats; D017208:Rats, Wistar; D012038:Regeneration / Q000187:drug effects*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D000077154:Rosiglitazone; D012720:Severity of Illness Index; D012844:Sincalide / Q000494:pharmacology; D045162:Thiazolidinediones / Q000494:pharmacology*; D013997:Time Factors
D047495:PPAR gamma; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D004247:DNA; D001120:Arginine; D012844:Sincalide